10055 Barnes Canyon Road
San Diego, CA 92121
Tel: (619) 353-0300
About Element Biosciences
At Element Biosciences, our mission is to empower the scientific community with more freedom and flexibility to accelerate our collective impact on humanity. Our proprietary approach to improving the signal-to-noise ratio allows us to provide groundbreaking innovations in surface chemistry, instrumentation, and biochemistry to drastically decrease the run cost and capital cost while delivering high sequencing data quality. Founded in 2017, our headquarters is located in San Diego, California, with additional operations located in the San Francisco Bay area.
40 articles about Element Biosciences
Element Biosciences Accelerates Data Discoveries with Amazon Omics
Element Biosciences, Inc. announced it is now leveraging a new Amazon Omics feature, Ready2Run workflows, to provide simple, powerful, and cost-effective analysis workflows.
Element Signs Multiple Global Distributors to Bring the Power of AVITI™ to Customers Around the World
Element Biosciences, Inc. has signed distribution agreements with companies based in Israel, South Korea, Australia, and the United Arab Emirates to bring its AVITI System to more customers around the world.
Phase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor Samples
Phase Genomics, Inc and Element Biosciences , the developer of an innovative DNA sequencing platform disrupting genomics, today released new details of their first collaboration leveraging Phase Genomics’ proprietary OncoTerra™ cytogenomics platform and the Element AVITI System for next generation sequencing (NGS).
Element Biosciences and Bio-Rad Partner to Deliver Seamless RNA Sequencing Workflow Between Element's AVITI™ System and Bio-Rad's SEQuoia™ Express and SEQuoia™ Complete Stranded RNA Library Prep Kits
Element Biosciences, Inc. — the developer of an innovative DNA sequencing platform disrupting genomics — and Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced a partnership to demonstrate the capabilities of the Bio-Rad SEQuoia RNA Sequencing Library Preparation portfolio on the Element AVITI™ Benchtop Sequencer.
Element to Present Data and Innovation Roadmap at AGBT
Element Biosciences, Inc. will present details about its new Avidity Cloudbreak™ technology and the company's innovation roadmap at the Advances in Genome Biology and Technology General Meeting Feb. 6-9, 2023, in Hollywood, FL.
Shawn Levy Elevated to Chief Scientific Officer and Senior Vice President of Applications
Element Biosciences, Inc announced the promotion of Shawn Levy , PhD, to Chief Scientific Officer and Senior Vice President of Applications.
Element Delivers $200 Genome on AVITI™ Benchtop Sequencing System
Element Biosciences, Inc.— the developer of an innovative DNA sequencing platform disrupting genomics — announced a new throughput-based option for its AVITI System that provides the highest quality sequencing on a benchtop for as low as $200 a genome, or $2 per gigabase.
Element CEO and Co-Founder Molly He to Speak at 41st Annual J.P. Morgan Healthcare Conference
Element Biosciences, Inc. announced that Element CEO and Co-Founder Molly He will speak at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 3:30 p.m. Pacific Time at the Westin St. Francis hotel in San Francisco.
Element Drives Industry Innovation with New Avidity Cloudbreak™ Technology and a 2 x 300 Kit
Element Biosciences, Inc. announced Avidity Cloudbreak technology, improvements to chemistry kits for the current Element AVITI™ System that reduce run times and enable even more applications.
Element Introduces New Element LoopSeq™ Long-Read Sequencing Kits Designed for the AVITI™ System
Element Biosciences, Inc. announced the availability of its Element LoopSeq long-read sequencing technology kits for AVITI, giving the Element AVITI System the power of both short- and long-read sequencing on the same instrument.
Element Biosciences Delivers 1 Billion Reads and Provides Industry's Lowest Cost for Single-Cell Sequencing
Element Biosciences, Inc. announced updated specifications to their AVITI System, increasing the platform's specifications from 800 million reads per flow cell to 1.0 billion reads per flow cell*, further reducing the price per Gigabase.
Element Biosciences Welcomes Former ThermoFisher Executive Shelly Peariso to their Growing Commercial Team
Element Biosciences, Inc. announced they are adding an industry veteran to their commercial team.
Element Biosciences Announces Reagent Price Guarantee for the Lifetime of the AVITI™ System
Element Biosciences Inc., developer of the Element AVITITM System, a new and disruptive DNA sequencing platform, announced it will implement no price increases to the entire range of AVITI reagents, including the sequencing kit, the AdeptTM and ElevateTM kits.
Element Science Announces First Patient Save with Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
Element Science, an innovative health technology company pioneering a next-generation digital wearable platform for high-risk cardiovascular patients transitioning from hospital to home, today announced the first patient save from a successful defibrillation early in the enrollment of the Investigational Device Exception (IDE) Study of its Jewel Patch Wearable Cardioverter Defibrillator (P-WCD).
The new space will enable Astellas to establish a global supply chain of gene therapies as well as widen the scope of the therapeutic products it creates.
Element Biosciences Announces First Customer Shipments and New Offerings for AVITI™ System
Element Biosciences, Inc., developer of the Element AVITI™ System, a new and disruptive DNA sequencing platform, announced it has shipped multiple AVITI systems to its first set of customers.
Miroculus Partners with Element Biosciences to Validate the Miro Canvas Digital Microfluidics Platform for the AVITI™ System
Miroculus Partners with Element Biosciences to Validate the Miro Canvas Digital Microfluidics Platform for the AVITI ™ System.
seqWell and Element Biosciences Partner to Demonstrate Sequencing Performance of Multiplexed plexWell Technology With the AVITI System
seqWell today announced a partnership with Element Biosciences Inc., developer of the Element AVITI™ System.
Pharma giant Merck announced it is expanding in both area and headcount with a new Cambridge, MA office. The company's plan is to add 160,000 square feet and 100 new employees.
Element Biosciences Debuts New Headquarters in San Diego
Element Biosciences Inc., developer of the Element AVITI™ System, a new and disruptive DNA sequencing platform, announced that it has moved its headquarters to the Alexandria Tech Center located on the 37-acre, 14-building campus in the Sorrento Mesa life science hub of San Diego, California.